NEW YORK, Feb. 8 - A recent federal budget proposal to increase by 60 percent the US Food and Drug Administration's fee to review a new-drug application may not be that much of a headache for young drug developers, experts say. And if ultimately approved, the increase will represent only a tiny fraction of what it costs to bring a drug to market.


To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.